Reply and the University of Milan Launch Experimental Research on Biological Computing Based on Cortical Labs’ CL1 Platform
28.1.2026 15:10:00 CET | Business Wire | Press Release
Reply [EXM, STAR: REY] today announced the start of a collaboration with the Department of Pathophysiology and Transplantation of the University of Milan, together with the “Centro Dino Ferrari” of the University of Milan - Ospedale Policlinico, for a new research and experimental initiative in the field of biological computing. The project aims to explore innovative approaches to learning and information processing through the integration of biological systems and digital technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128715625/en/
This initiative represents the starting point of an advanced research programme aimed at exploring new computational paradigms.
At the core of the initiative is the CL1 biological computer developed by Cortical Labs, an Australian biotechnology company. Unlike conventional silicon-based computing architectures, this technology leverages the processing capabilities of living human neurons integrated with software systems. The CL1 platform incorporates approximately 800,000 neurons, which receive inputs, process information, and generate outputs in the form of electrical activity, enabling direct interaction between the software and biological intelligence.
Building on previous studies conducted by Cortical Labs, which demonstrated that neuronal cultures can learn the game Pong in just a few minutes using significantly fewer training examples than conventional artificial intelligence systems, the Reply–University of Milan research project will focus on analyzing the learning dynamics of biological neurons, comparing their energy efficiency with traditional computing architectures, and assessing the robustness, reproducibility, and long-term stability of neuron-based computing systems.
“This initiative represents the starting point of an advanced research programme aimed at exploring new computational paradigms. The goal is to assess their potential practical impact and to understand their possible implications in terms of solutions and benefits for organisations,” said Filippo Rizzante, CTO of Reply.
“This collaboration opens a new frontier in the study of biological computation,” stated Prof. Stefania Corti, Full Professor of Neurology at the University of Milan and Director of Neuromuscular and Rare Diseases at the Milan Policlinico. “The integration of active neurons with digital systems offers unprecedented opportunities to investigate learning mechanisms and neural plasticity, with potential implications for both neuroscience research and computational innovation.”
“Working with biological neurons in a computational context allows us to explore fundamental questions about how neural networks process and adapt to information,” added Prof. Linda Ottoboni, Researcher at the Department of Medical-Surgical Pathophysiology and Transplantation of the University of Milan. “This interdisciplinary project combines neuroscientific expertise with cutting-edge technologies to advance our understanding of biological intelligence.”
“The CL1 platform offers a unique opportunity to study the physiological dynamics of neuronal networks in a controlled computational environment,” said Prof. Carlo Capelli, Full Professor of Physiology at the Department of Medical-Surgical Pathophysiology and Transplantation of the University of Milan. “Understanding how biological systems process information at the cellular level could open new perspectives in integrative physiology research.”
“From a biomechanical and physiological standpoint, this project allows us to investigate the energy efficiency of biological computation compared to artificial systems,” added Prof. Alberto Minetti, Full Professor of Physiology and Biomechanics at the University of Milan. “The potential for studying adaptive mechanisms in living neural networks is remarkable. The results of simple dynamic balance experiments, for example, could be achieved using a significantly smaller number of ‘biological’ neurons.”
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialized companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
University of Milan – Department of Pathophysiology and Transplantation
The Department of Pathophysiology and Transplantation of the University of Milan is a center of excellence in biomedical research focused on translational medicine. Its activities range from cellular physiology to neuroscience and the development of advanced therapeutic strategies, with the aim of translating scientific discoveries into clinical and technological innovation. Researchers involved: Prof. Stefania Corti and Prof. Linda Ottoboni, Dino Ferrari Center, University of Milan, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan, Italy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128715625/en/
Contacts
Media contact:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +39 0117711594
Irene Caia
i.caia@reply.com
Tel. +39 02 535761
University of Milan
Press Office, University of Milan
ufficiostampa@unimi.it
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Menicon’s Largest Malaysia Plant Begins Commercial Production5.2.2026 10:00:00 CET | Press Release
Menicon Co., Ltd. is pleased to announce that its new manufacturing facility in Kedah, Malaysia, has commenced commercial production. The plant strengthens Menicon’s long-standing commitment to technological excellence, uncompromising quality, and a stable global supply of contact lenses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127294120/en/ The newly opened Malaysia plant is Menicon’s largest site to date and is dedicated exclusively to producing 1-DAY lenses. As global demand for 1-DAY lenses continues rising and the industry faces widespread supply constraints, Menicon has made significant capital investments to expand production capacity—even amid the uncertainties presented by the COVID-19 pandemic. Construction of phase 1, currently underway, will provide capacity for up to 500 million lenses per year. The construction plan is strategically formulated to extend through phase 4, allowing for further expansion
Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 09:00:00 CET | Press Release
Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press Release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press Release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press Release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom